Hologic (HOLX) officer logs small tax-related share withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Hologic executive Mark W. Horvath, President of Breast & Skeletal Health, reported a small administrative share disposition related to taxes. On February 10, 2026, 113 shares of common stock were withheld at $75.15 per share to cover tax obligations from settling restricted stock units.
After this tax-withholding transaction, Horvath directly beneficially owns 23,026 shares of Hologic common stock. This total includes 4,605 performance stock units/restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Horvath Mark W.
Role
President, Breast & Skeletal
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 113 | $75.15 | $8K |
Holdings After Transaction:
Common Stock — 23,026 shares (Direct)
Footnotes (1)
- Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied. Includes 4,605 performance stock units/restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.
FAQ
What insider transaction did Hologic (HOLX) report for Mark W. Horvath?
Hologic reported that executive Mark W. Horvath had 113 shares of common stock withheld to cover tax obligations. The shares relate to the settlement of restricted stock units after service-based vesting conditions were met, rather than an open market sale or purchase.
What do the deferred units in the Hologic (HOLX) Form 4 represent?
The filing notes 4,605 performance stock units and restricted stock units whose settlement is deferred under Hologic’s Deferred Equity Plan. These units reflect equity awards already granted to Mark W. Horvath, with actual share delivery postponed according to the plan’s deferred settlement terms.
What is Mark W. Horvath’s role at Hologic (HOLX) in this insider filing?
Mark W. Horvath is identified as an officer of Hologic, serving as President, Breast & Skeletal. His Form 4 filing reports an administrative tax-withholding share disposition related to equity compensation, rather than a voluntary purchase or sale in the open market.